- Home
- SER vs BTAI Comparison
SER vs BTAI Comparison
Compare SER & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SER | BTAI |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | 13 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4M | 35.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | SER | BTAI |
|---|---|---|
| Price | $1.54 | $1.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $13.00 | ★ $25.33 |
| AVG Volume (30 Days) | 98.2K | ★ 952.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $134.46 | N/A |
| Revenue Next Year | N/A | $261.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.47 | $1.17 |
| 52 Week High | $7.92 | $8.08 |
Technical Indicators
Market Signals| Indicator | SER | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 36.19 | 56.40 |
| Support Level | $1.53 | $1.50 |
| Resistance Level | $1.86 | $2.13 |
| Average True Range (ATR) | 0.12 | 0.13 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 26.92 | 83.25 |
Price Performance
Historical ComparisonAbout SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.